Recent news articles have described long-term success in early clinical trials for the pancreatic cancer mRNA vaccine.
Pancreatic cancer is one of the more frightening cancers because it’s difficult to diagnose early, and treatments have limited success. So, a new tool to fight this cancer is reason to celebrate.
This article will review how the pancreatic cancer mRNA vaccines work and the current long-term success in early studies.

Pancreatic cancer
Before I discuss the vaccine, here are some facts about pancreatic cancer:
- According to the American Cancer Society, the five-year survival rate for all pancreatic cancer stages is around 13%.
- An estimated 67,440 people (34,950 men and 32,490 women) will be diagnosed with pancreatic cancer in 2025.
- About 51,980 people (27,050 men and 24,930 women) will die of pancreatic cancer in 2025.
- Because early symptoms of pancreatic cancer may be missed, it is usually diagnosed in later stages, which leads to only a one-year survival after diagnosis. There are no routine screenings for pancreatic cancer, such as a colonoscopy or mammogram.
- Treatment of pancreatic cancer usually requires surgery plus adjuvant therapies like chemotherapy and radiation therapy. Of course, the success rate of this strategy is lower with later-stage pancreatic cancer. Only about 20% of cases are operable
- Less than 13% of people diagnosed with pancreatic cancer live for more than five years.

Pancreatic cancer mRNA vaccine
An mRNA cancer vaccine helps create neoantigen-specific T-cells that attack pancreatic cancer cells, which, in turn, helps destroy them. The mRNA vaccine for pancreatic cancer is individualized; that is, each person receives an mRNA vaccine engineered to match their unique cancer cells. The mRNA cancer vaccine developed for person X will probably not work in person Y, even though they may share common cell-surface antigens.
I need to make an important point — a cancer “vaccine” is a bit of a misnomer. These vaccines induce an immune response, but are not preventative, like vaccines for infectious pathogens — this new pancreatic cancer mRNA vaccine is a treatment.
This mRNA vaccine is individualized, meaning it codes for antigenic proteins on each person’s pancreatic cancer cells. Every person has slightly different antigens, even if they have the same cancer type. However, this vaccine may provide immunity to a recurrence of the cancer, so, in a sense, it is also preventative.
So, how does this “vaccine” work? The mRNA cancer vaccine trains the immune system to attack cancer cells that may have been missed by surgery or chemotherapy, or have metastasized to another location. But, and this is important, it probably would not affect another type of tumor. For example, this pancreatic cancer mRNA vaccine will probably be useless against colorectal cancer.
Furthermore, this cancer will be used in conjunction with surgery, and possibly chemotherapy, as part of an overall treatment strategy for pancreatic cancer. This vaccine ought to be considered a form of immunotherapy.
The mRNA vaccine for pancreatic cancer is usually given after recovery from surgery. During the post-surgery period, the mRNA vaccine is developed for that individual patient and is given to them as part of the treatment strategy. During and after receiving the vaccine, the patient will probably also receive chemotherapy. According to clinical research, this is the best way to have the highest success rate.

Genentech-BioNTech cevumeran mRNA vaccine
The pancreatic cancer mRNA vaccine was developed by BioNTech, the German pharmaceutical company that also developed one of the COVID-19 mRNA vaccines in partnership with Pfizer. I reviewed the early results last year, but now we have three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy (“iNeST”) candidate mRNA vaccine, cevumeran, in patients with resected pancreatic ductal adenocarcinoma.
To be eligible for the trial, a patient’s cancer had to be in the pancreas and be removable with surgery. Those conditions occur in just between 20% and 25% of pancreatic cancer patients.
Patients undergo surgery to remove the tumor, which is then sequenced to make a personalized vaccine specific to the patient’s cancer. The vaccine is developed in four to six weeks while patients recover from surgery. Patients receive six weekly injections, and following six months of standard chemotherapy, patients receive six more vaccines as boosters.
Phase 1 clinical trial results were published in 2023 and showed some promising findings. At a median follow-up of 18 months after surgery, eight patients with immune responses to the mRNA vaccine, cevumeran, had significantly longer recurrence-free survival than the eight patients with no immune response, with a median of 13.4 months.
In a paper published on 19 February 2025 in Nature, Vinod P Balachandran, MD, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, and colleagues examined the same 16 patients discussed in the 2023 study, 3.2 years after treatment.
The data showed:
- In 8 of 16 patients, cevumeran elicited an immune response up to three years post-administration, measured by activated T cells. The persistence of T cells was associated with a longer median recurrence-free survival in cancer vaccine responders.
- In two of the eight patients who had a strong immune response, their cancer returned.
- Seven of the eight non-responding patients had their cancers return within that 3.2-year window
The still-recruiting phase 2 clinical trial should provide more data about the effectiveness of the vaccine. It is sponsored by Genentech and BioNTech and will include 260 subjects in 14 locations in the USA. The study will compare the endpoints of patients with pancreatic cancer who receive cevumeran plus Atezolizumab and mFOLFIRINOX, two chemotherapy drugs, to patients who receive mFOLFIRINOX alone. The goal of the study is to determine the safety and efficacy of cevumeran, the mRNA vaccine, and to determine if the vaccine improves outcomes compared to chemotherapy alone.
NBC reported that the six patients who were successfully treated with the mRNA vaccine have survived for over six years. Of course, we need larger trials with more subjects to begin to confirm the effectiveness of this vaccine treatment for pancreatic cancer.
All of this is good news; we may have a powerful treatment for a scary cancer. Of course, the anti-vaccine people may block it because the vaccine is mRNA-based.
Citations
- Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D’Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O’Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10. PMID: 37165196; PMCID: PMC10171177.
- Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, Pang N, Ohmoto A, Amisaki M, Zebboudj A, Odgerel Z, Bruno EM, Zhang SL, Cheng C, Elhanati Y, Derhovanessian E, Manning L, Müller F, Rhee I, Yadav M, Merghoub T, Wolchok JD, Basturk O, Gönen M, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D’Angelica MI, Kingham TP, Soares KC, Jarnagin WR, Drebin J, O’Reilly EM, Mellman I, Sahin U, Türeci Ö, Greenbaum BD, Balachandran VP. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025 Mar;639(8056):1042-1051. doi: 10.1038/s41586-024-08508-4. Epub 2025 Feb 19. PMID: 39972124; PMCID: PMC11946889.
Help the Skeptical Raptor keep writing about innovative vaccines
There are four ways you can help contribute to keeping this website running at full speed:
- GoFundMe.
- Subscribing via Patreon.
- Buying your favorite stuff on Amazon.
- Sharing this article on Social Media.
Discover more from Skeptical Raptor
Subscribe to get the latest posts sent to your email.
